Addex Therapeutics announced that shareholders approved all board proposals at its 2024 Annual General Meeting, with 33.79% of outstanding capital represented. Key approvals included the 2023 annual report, financial statements, and compensation report. Board members, including Chairman Dr. Vincent Lawton, were re-elected, and BDO SA was reappointed as auditor.Shareholders also approved amendments to the Articles of Association, including an increase in capital band and conditional share capital. These changes align with revised corporate law and address matters related to shareholders, general meetings, board attributions, and compensation limits. The company's lead drug candidate, ADX71149, recently completed a Phase 2 study for epilepsy treatment.Addex is advancing multiple drug development programs, including dipraglurant for Parkinson's disease-related dyskinesia, and collaborations with Indivior on GABAB PAM for substance use disorder and chronic cough. The company also holds a 20% stake in Neurosterix LLC, which is developing allosteric modulators for various neurological disorders.

Addex Therapeutics announced that shareholders approved all board proposals at its 2024 Annual General Meeting, with 33.79% of outstanding capital represented. Key approvals included the 2023 annual report, financial statements, and compensation report. Board members, including Chairman Dr. Vincent Lawton, were re-elected, and BDO SA was reappointed as auditor.Shareholders also approved amendments to the Articles of Association, including an increase in capital band and conditional share capital. These changes align with revised corporate law and address matters related to shareholders, general meetings, board attributions, and compensation limits. The company's lead drug candidate, ADX71149, recently completed a Phase 2 study for epilepsy treatment.Addex is advancing multiple drug development programs, including dipraglurant for Parkinson's disease-related dyskinesia, and collaborations with Indivior on GABAB PAM for substance use disorder and chronic cough. The company also holds a 20% stake in Neurosterix LLC, which is developing allosteric modulators for various neurological disorders.